Monday, Jun 8, 1992
South San Francisco, Calif. -- June 8, 1992 --Genentech, Inc. (NYSE: GNE) today announced its successful defense against oppositions to the granting of its European patent for recombinant t-PA (tissue plasminogen activator). The victory followed a 2-day hearing of arguments against the patent by seven other companies at the European Patent Office (EPO) in Munich last week.
Under European patent law, granted patents are subjected to a review period during which opposing parties may attempt to demonstrateunpatentability of the claims allowed in the subject patent. The seven companies who raised oppositions to the Genentech patent were: Kabivitrum AB, The Wellcome Foundation Limited, Celltech Limited, Toyo Boseki Kabushiki Kaisha, Abbott Laboratories, Behringwerke AG, and Boehringer Mannheim GMBH.
"This is the third instance in which the validity of these patent claims has been affirmed, " said Dr. Stephen Raines, vice president, intellectual propertyfor Genentech, referring to the previous legal victories in the United States and Japan. "The actions taken by the EPO further strengthen Genentech's worldwide recombinant t-PA patent position."
Recombinant t-PA is a thrombolytic agent used to dissolve blood clots in heart attack patients and restore normal blood flow to the heart muscle. Through an exclusive license from Genentech, Boehringer Ingelheim currently markets t-PA in Europe under the brand name Actilyse®.
Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant medical needs. The company has headquarters in South San Francisco, California and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.
# # #